- Lucy Chambers / Slaughter and May
- Matt Evans / Jones Day
- Miranda Cole / Covington & Burling LLP
- John Harkrider / Axinn, Veltrop, & Harkrider LLP
- Tara Reinhart / Skadden, Arps, Slate, Meagher & Flom LLP
- Nelson Jung / Clifford Chance
Presented by the Mergers and Acquisitions Committee.
Thermo Fisher Scientific/Roper Technologies, Illumina/Pacific Biosciences, Roche/Spark, Sabre/Farelogix – just four of the global deals over which the UK’s Competition & Markets Authority has recently asserted merger control jurisdiction and, in the case of three of them, either blocked or caused abandonment.
To many international eyes, the CMA has been adopting an aggressive approach to jurisdiction and asserting itself by sustaining concerns about international deals in circumstances where other antitrust agencies and courts have not shared those concerns. Is the CMA the new global antitrust policeman when it comes to merger control and is this a taste of things to come in the Brexit era? Have its decisions, on jurisdiction and substance, been justified, or is it overextending its reach?
This discussion, co-hosted by the ABA Antitrust Section’s Mergers & Acquisition Committee and the Competition Section of the Law Society of England & Wales, brings together leading practitioners from both sides of the Atlantic to explore and perhaps explain the CMA’s recent approach to merger control.